Dark Forest Capital Management LP Acquires New Shares in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Dark Forest Capital Management LP bought a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) during the 2nd quarter, Holdings Channel.com reports. The institutional investor bought 11,033 shares of the company’s stock, valued at approximately $86,000.

A number of other hedge funds also recently added to or reduced their stakes in GDRX. Rubric Capital Management LP bought a new position in shares of GoodRx during the fourth quarter worth about $39,348,000. American Century Companies Inc. acquired a new position in GoodRx during the 2nd quarter valued at about $18,183,000. Rip Road Capital Partners LP grew its position in GoodRx by 25.8% in the 4th quarter. Rip Road Capital Partners LP now owns 1,763,277 shares of the company’s stock worth $11,814,000 after purchasing an additional 361,294 shares during the last quarter. Picton Mahoney Asset Management increased its stake in shares of GoodRx by 24.3% in the second quarter. Picton Mahoney Asset Management now owns 607,090 shares of the company’s stock valued at $4,736,000 after purchasing an additional 118,703 shares during the period. Finally, GSA Capital Partners LLP bought a new stake in shares of GoodRx during the first quarter valued at approximately $1,638,000. 63.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several analysts recently commented on GDRX shares. Raymond James upgraded GoodRx from an “outperform” rating to a “strong-buy” rating and set a $10.00 target price on the stock in a research report on Friday, August 9th. Morgan Stanley raised their price target on GoodRx from $7.00 to $9.50 and gave the company an “equal weight” rating in a report on Monday, June 10th. UBS Group reduced their price objective on shares of GoodRx from $9.00 to $8.50 and set a “neutral” rating for the company in a report on Friday, August 9th. Royal Bank of Canada reissued an “outperform” rating and set a $10.00 target price on shares of GoodRx in a research note on Friday, August 16th. Finally, Citigroup reduced their price target on shares of GoodRx from $11.00 to $10.00 and set a “buy” rating for the company in a research note on Friday, August 9th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, nine have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $9.36.

Insider Activity at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of GoodRx stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $7.86, for a total transaction of $83,921.22. The transaction was disclosed in a legal filing with the SEC, which is available through this hyperlink. 4.17% of the stock is owned by insiders.

GoodRx Stock Performance

GDRX opened at $6.94 on Tuesday. The company has a quick ratio of 7.32, a current ratio of 7.32 and a debt-to-equity ratio of 0.96. The firm has a market cap of $2.60 billion, a PE ratio of -694.00, a P/E/G ratio of 3.38 and a beta of 1.38. The business has a fifty day simple moving average of $7.77 and a 200-day simple moving average of $7.57. GoodRx Holdings, Inc. has a fifty-two week low of $4.14 and a fifty-two week high of $9.26.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Thursday, August 8th. The company reported $0.08 earnings per share for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). GoodRx had a positive return on equity of 3.63% and a negative net margin of 7.57%. The company had revenue of $200.60 million during the quarter, compared to analysts’ expectations of $200.47 million. During the same period in the prior year, the business posted $0.02 EPS. The company’s revenue for the quarter was up 5.7% compared to the same quarter last year. As a group, equities analysts predict that GoodRx Holdings, Inc. will post 0.14 EPS for the current fiscal year.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.